Overview of Urfocin TM

Quick Facts

Property	Description
Active ingredient	Fosfomycin (typically as Fosfomycin trometamol)
Form	Granules for oral solution / Oral powder
Pharmacological class	Antibiotic, Cell wall synthesis inhibitor
General Purpose	Eliminate susceptible bacterial pathogens
Origin	Synthetic (Phosphonic acid derivative)

What Type of Medicine is Urfocin ^TM (Fosfomycin)?

Urfocin ^TM is a prescription-only medicine that contains the active ingredient Fosfomycin, which is a specialized antibiotic and antimicrobial agent. It belongs to the unique pharmacological class of phosphonic acid derivatives and is fundamentally a compound of synthetic origin.

Fosfomycin possesses a broad-spectrum activity against a wide range of clinically significant bacteria. Its distinct structure and mechanism mean it is utilized for its potential role in managing bacterial infections, particularly where typical resistance patterns may be a factor.

Composition and Physical Form of Urfocin ^TM

The essential component is the active ingredient, Fosfomycin, typically administered as the salt Fosfomycin trometamol, which is designed to enhance its absorption after ingestion. Urfocin ^TM is supplied as granules for oral solution or an oral powder, constituting a single-component product intended for oral administration after being dissolved in a liquid vehicle.

This specific formulation ensures that the Fosfomycin trometamol salt is rapidly absorbed for effective systemic delivery of the antimicrobial agent throughout the body. The preparation as a dissolved solution is a distinct feature when compared to conventional solid tablet forms, optimizing its bioavailability for its intended action.

General Purpose and Unique Action of this Antibiotic

The primary purpose of Urfocin ^TM is to achieve the rapid elimination of susceptible bacterial pathogens through a potent bactericidal action. This means the medicine is designed to actively kill the targeted bacteria rather than merely inhibiting their growth.

The bactericidal effect is considered unique because Fosfomycin prevents bacteria from even starting to build their protective outer layer, the cell wall. By irreversibly interfering with the initial steps of the cell wall synthesis, the antibiotic acts as a highly specialized and effective Cell wall synthesis inhibitor, clinically recognized for its reliable action.

What side effects are possible with Urfocin TM?

Possible Side Effects and Safety Information

Official regulatory documents classify the possible adverse reactions associated with fosfomycin trometamol across several System Organ Classes, defining their expected frequency based on clinical data. The most frequently observed effects generally involve the gastrointestinal and nervous systems.

Frequency-Classified Adverse Reactions

The adverse reactions listed in official labeling are primarily categorized by frequency:

Classification	Examples of Adverse Reactions (SOC)
Common (ge 1/100 to < 1/10)	Diarrhea, Nausea, Headache, Dizziness, Abdominal pain, Vulvovaginitis.
Uncommon (ge 1/1,000 to < 1/100)	Vomiting, Rash, Urticaria.

Serious Adverse Reactions and Safety Notes

The regulatory profile documents rare but serious adverse reactions, including severe Hypersensitivity events such as anaphylaxis and anaphylactic shock. Additionally, Antibiotic-Associated Colitis (Clostridioides difficile-associated diarrhea or CDAD) is a documented risk that can range from mild to life-threatening.

The official labeling notes that effects such as diarrhea are typically self-limited and resolve spontaneously. However, CDAD may occur during or subsequent to the administration. Patients are advised that Dizziness is a reported effect that may influence the ability to drive or use machinery.

Population-Specific Safety Considerations

Official statements address specific populations. Use during pregnancy should only be considered if clearly necessary, as the medicine crosses the placenta. For the paediatric population, safety and efficacy in children below 12 years of age have not been established. A key safety limitation is the need to avoid co-administration with Metoclopramide, which has been shown to reduce fosfomycin concentrations in the body.

Overdose and Emergency Response

The official regulatory profile for an overdose of Urfocin (Fosfomycin trometamol) details specific clinical manifestations and mandated emergency actions based on documented experience.

Documented Clinical Signs

Experience with an overdose of the oral formulation is generally limited, but clinical signs reported in overdose or high-dose exposure primarily involve sensory disturbances. These documented manifestations include impaired hearing, vestibular loss (symptoms of dizziness or imbalance), metallic taste, and a general decline in taste perception.

When to Seek Immediate Medical Help

If an overdose is suspected, seek emergency medical attention immediately. Regulatory guidance mandates that emergency services must be contacted if the individual exhibits severe clinical deterioration. These triggers include collapse, seizure, trouble breathing, or being unable to be awakened.

Official Management and Monitoring

Management of an overdose is symptomatic and supportive. To promote the urinary elimination of the active substance from the body, rehydration is recommended. The active substance is known to be effectively cleared by haemodialysis. Clinical monitoring is required in a medical setting, focusing specifically on the patient’s plasma or serum electrolyte levels. No specific antidote is detailed in the official regulatory labeling.

Therapeutic Uses of Urfocin TM

What Urfocin ^ TM treats: Main Uses and Benefits

Urfocin is primarily used to address susceptible bacterial pathogens in the lower urinary tract, which are responsible for acute uncomplicated cystitis (bladder infection) in women and adolescent girls. This medicine is commonly used to help with the associated symptom clusters.

Targeted Symptom Relief and Clinical Contexts

Urfocin is generally applied in settings where symptoms are related to inflammatory or irritative states. It is commonly used across conditions presenting with acute episodes like uncomplicated cystitis and, in specialized cases, asymptomatic bacteriuria in pregnant women. This medicine is relevant for managing symptoms that interfere with daily comfort, such as the acute burning sensation during urination (dysuria), sudden urgency, and disruptive urinary frequency. The medication supports the patient during these difficult episodes, providing support that helps ease the overall symptom burden. It is also relevant when infections involve multidrug-resistant (MDR) bacteria, being applicable in contexts involving heightened systemic burden.

Quick Fact: Support for Acute Voiding Symptoms
Primary Focus: Symptom clusters that interfere with daily functioning, specifically dysuria and urinary urgency.
Key Benefit: Contributes to improved day-to-day comfort during symptomatic periods when symptoms are more noticeable.
Relevant Context: Applied in clinical settings that involve acute or unstable symptom patterns, especially in vulnerable patient groups.

Eligibility and Restrictions for Use

Who can and cannot use Urfocin ^ TM?

Regulatory documents establish clear restrictions on who can and cannot use Urfocin ^ TM, which is representative of the fluoroquinolone class of antibiotics. The drug is contraindicated in several specific populations, meaning it must not be used:

Patients with a known history of Myasthenia Gravis (MG) due to the risk of exacerbating muscle weakness.
Individuals with a known severe hypersensitivity to Urfocin ^ TM or any other fluoroquinolone antibacterial agent.
Patients who have previously experienced a disabling or potentially irreversible serious adverse reaction (such as severe tendon, nerve, or central nervous system effects) linked to any fluoroquinolone.

Use is also strictly contraindicated in pediatric patients (under 18 years of age), during pregnancy, and during breastfeeding due to the potential for serious adverse effects on developing cartilage.

Furthermore, for certain less severe conditions, such as uncomplicated urinary tract infections, the drug is subject to a Limitation of Use statement. This means Urfocin ^ TM should be reserved only for patients who have no alternative treatment options.

What should I know about interactions with other medicines?

The official regulatory profile for Urfocin^ TM (Fosfomycin) establishes specific drug and substance interactions, categorized by pharmacokinetic and pharmacodynamic effects.

Prohibited and Restricted Combinations

Co-administration is formally contraindicated with Live Vaccines, including the BCG, Cholera, and Typhoid vaccines. This restriction is due to pharmacodynamic antagonism, where the antibiotic action may interfere with the intended effect of the live bacterial vaccines.

A clinically significant pharmacokinetic interaction occurs with the motility-enhancing medicine Metoclopramide. Co-administration has been officially documented to lower the plasma and urinary concentrations of fosfomycin, leading to a reduction in systemic drug exposure. For this reason, co-administration with Metoclopramide should be avoided.

Timing and Substance Interactions

The medicine’s absorption is sensitive to food. Ingesting Urfocin^ TM with a meal is documented to delay absorption and cause a slight decrease in peak concentrations (Cmax). Regulatory text specifies that it is preferable to take the medicine on an empty stomach or separated from meals by approximately two to three hours.

A pharmacodynamic caution is advised for the co-administration of this antibiotic with Oral Anticoagulants. Official documents note a risk of alteration in the International Normalized Ratio (INR). Furthermore, regulatory records state that formal interaction studies have only been performed in adults, establishing a limitation of documented data for the paediatric population.

Mechanism of Action

Irreversible Enzyme Blockade and Cell Wall Disruption

Urfocin is actively transported into the bacterial cell utilizing the native GlpT and UhpT transporters. Once intracellular, it acts as a phosphoenolpyruvate analog to achieve irreversible covalent inhibition of the essential enzyme MurA (UDP-N-acetylglucosamine enolpyruvyl transferase). This targeted enzymatic blockade immediately halts the synthesis of the peptidoglycan precursor, which is the foundational component of the bacterial cell wall .

Cascade to Osmotic Cell Lysis

The failure to build or repair the rigid cell wall prevents the bacteria from maintaining structural integrity against internal osmotic pressure. This leads directly to cell lysis (the bursting of the bacterial cell), a primary bactericidal physiological consequence of this mechanism. The mechanism's functional expression can be limited by bacterial adaptations such as mutations that impair the drug's transporters or the production of inactivating enzymes that chemically neutralize Urfocin.

Dosage and Administration Information

Urfocin TM, containing the active ingredient Fosfomycin trometamol, is utilized via the oral route as a high-concentration, short-course treatment. The administration protocol follows a single-dose regimen. The entire treatment consists of one sachet containing a standard dose of 3 grams of Fosfomycin. Repeated doses are not indicated for managing a single episode of acute uncomplicated cystitis.

The administration of the medicine requires specific preparation. The complete content of the granules from the sachet must first be dissolved into approximately three to four ounces of cool water. The resulting solution must be consumed immediately after preparation, and the granules must never be swallowed dry.

To ensure optimal absorption, the single dose is taken on an empty stomach, meaning two to three hours before or after consuming food. Furthermore, the dose is typically administered before bedtime following the emptying of the bladder. This contextual timing is intended to maintain peak concentrations of the medicine in the urinary tract for an extended duration.

Usage restrictions apply to certain populations. The 3-gram single dose is for use in female adolescents who are over 12 years of age. However, this oral formulation is not recommended for patients with severe reduction in kidney function, specifically those with a creatinine clearance below 10 mL/min.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Urfocin ^ TM

Evidence for Use in Acute Uncomplicated Cystitis (Bladder Infection)

Urfocin ^ TM was evaluated in research contexts involving conditions associated with acute or disruptive episodes of lower urinary tract symptoms, such as physical discomfort and urgency. Research has explored the medicine's use primarily in non-pregnant women and adolescent girls who experience these conditions.

The core evidence comes from Randomized Controlled Trials (RCTs) and Systematic Reviews that combine the findings of multiple trials. These studies examined two primary outcomes: the disappearance of symptoms (clinical resolution) and the eradication of the bacteria causing the infection from the urine (microbiological resolution). The majority of research consists of comparative studies where the single dose of Urfocin ^ TM was evaluated against short-course regimens of other standard antibiotics.

Findings describe patterns observed in the studies where outcomes related to physical discomfort and microbiological clearance were monitored. The research examined how the single dose compared to alternative short-course regimens across these measurements.

Evidence for Use in Asymptomatic Bacteriuria during Pregnancy

Research has also examined Urfocin ^ TM for its use in pregnant women who have asymptomatic bacteriuria—the presence of bacteria in the urine without noticeable symptoms. This condition was studied because of the potential outcomes related to systemic or functional imbalance that may arise later in the pregnancy.

The relevant research primarily involves Randomized Controlled Trials (RCTs) that compared the single-dose regimen with other short-course antibiotics that were evaluated in research for pregnant populations. These studies monitored the specific microbiological outcome of bacterial eradication from the urine.

Summary of Evidence Consistency and Research Gaps

Overall, the research for the primary approved use (uncomplicated cystitis) is based on a large volume of comparative RCTs and systematic reviews. This evidence quality varies across studies, but the overall body of research contributes to a substantial evidence base for this specific short-term condition.

However, certain areas remain uncertain. Long-term effects are not fully established, particularly concerning preventing future episodes. Furthermore, Data for certain groups, including children under 12, are still emerging or considered insufficient for regulatory certainty. Research provides context but not individual predictions, and study results reflect the specific conditions under which they were conducted.

Key Studies & References Fosfomycin for Uncomplicated Urinary Tract Infection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Urfocin TM (FAQ)

Q: How quickly does Urfocin TM usually start working?

Studies and official information indicate that this medicine achieves its maximum concentration rapidly. Following the single dose, the medicine is intended to maintain high concentrations in the urine for approximately 24 to 48 hours to maintain therapeutic activity.

Q: What is the average duration of a standard Urfocin TM course?

According to the official product information, Urfocin TM is intended as a short-course treatment. Regulatory guidelines specify that the entire course of treatment consists of a single dose.

Q: Can Urfocin TM cause drowsiness or make you tired?

Official adverse reaction lists commonly include dizziness as a side effect of the oral formulation. While dizziness is related to the central nervous system, effects like generalized tiredness or fatigue are not listed as common for the oral granules.

Q: Can I take vitamins or supplements while using Urfocin TM?

As a general precaution, official patient information notes the importance of informing a healthcare provider about all substances being taken. This includes any vitamins, nutritional supplements, or herbal products being used.

Q: Is it true that Urfocin TM can interact with antacids?

Official studies indicate that certain acid-reducing medicines, like the H2-blocker cimetidine, do not affect the way this medicine works. However, regulatory information notes that taking it on an empty stomach may result in slightly higher peak concentrations.

Q: How soon after stopping Urfocin TM will the drug be completely out of my system?

Regulatory documents state that the drug's elimination is primarily through the kidneys. The mean elimination half-life—the time required for the drug concentration in the body to drop by half—is reported to be approximately 5.7 hours in individuals with normal kidney function.

Q: What happens if I miss a dose of Urfocin TM?

Since the medicine is a single-dose treatment, the concept of a missed dose is slightly different from multi-day courses. Regulatory information regarding a missed dose states that it may be taken as soon as it is remembered, with the instruction that it is taken on an empty stomach, meaning waiting two to three hours after eating a meal.

Q: Are there any studies looking at the long-term effects of Urfocin TM?

Official research summaries indicate that the body of evidence for the primary approved use is substantial. However, these same summaries mention that long-term effects are not fully established, particularly regarding the prevention of future episodes of infection.

Q: What official documents say about who should not take Urfocin TM?

Official prescribing information lists specific contraindications, which are conditions where the medicine should not be used. These include known severe hypersensitivity to the medicine. The oral formulation is also generally not recommended for patients with severely reduced kidney function.

Q: Is Urfocin TM suitable for use by children?

Official regulatory documents state that the safety and effectiveness of the oral granules have not been established in children under 12 years of age. For adolescents, the official guidance notes that the dosage is to be determined by a healthcare professional.

Q: Can older adults or seniors take Urfocin TM?

The official prescribing information approves the single 3-gram dose for use in females 18 years of age and older. No specific contraindication related solely to older age is generally noted, but the label notes that severe reduction in kidney function is a restriction for use.

Q: Does Urfocin TM change the way birth control pills work?

Official interaction data indicates that this medicine may decrease the effectiveness of certain oral contraceptives. This is thought to occur through the alteration of the natural bacteria in the intestinal tract.

Q: Is it normal to feel a metallic taste after taking Urfocin TM?

A change in taste has been reported as an adverse reaction in the post-marketing surveillance for the injectable form of fosfomycin. This specific side effect is not listed as a common reaction associated with the oral granules.

Q: Does Urfocin TM need to be taken with food?

The FDA-approved label states that this medicine can be taken without regard to food. However, official information notes that taking the medicine on an empty stomach may result in slightly higher peak concentrations in the body.

Q: What types of infections is Urfocin TM specifically not indicated for?

The oral granules are specifically indicated for acute uncomplicated cystitis (a bladder infection). The oral formulation is not indicated or approved for treating serious systemic infections, such as infections of the heart, lungs, or bones.

Q: Is Urfocin TM a controlled substance?

This medicine is classified as a prescription-only drug. However, regulatory records confirm that it is not listed as a controlled substance under the Controlled Substances Act (CSA) Schedule.

Q: Is Urfocin TM safe to use during pregnancy, according to official sources?

Official sources state that the medicine crosses the placenta, and its use during pregnancy is to be considered only if clearly necessary.

Q: Can Urfocin TM be used while breastfeeding?

Official documents state that it is currently unknown whether the medicine is excreted into human milk. Use during breastfeeding is subject to caution.

Q: What official warnings exist about Urfocin TM and liver function?

The medicine is known to be primarily cleared by the kidneys, not the liver. While rare, post-marketing reports have included cases of cholestatic jaundice and hepatic necrosis (severe liver damage), though a direct causal link has not been established in all cases.

Q: Does Urfocin TM have a risk of causing tendon problems?

This medicine is a unique type of antibiotic (a phosphonic acid derivative) and belongs to a different class than those known to cause tendon problems. There is no specific tendon rupture warning in the official labeling for this medicine.

Q: Is Urfocin TM known to interact with blood thinners?

Official warnings note caution regarding co-administration with oral anticoagulants, which are often called blood thinners. This is due to a documented risk of alteration in the International Normalized Ratio (INR), a measure of blood clotting time.

Q: How is Urfocin TM typically described in official drug information sheets?

Official sheets describe this medicine as a prescription-only, synthetic, broad-spectrum antibiotic. It belongs to the unique phosphonic acid derivative class and is known for its potent bactericidal action against susceptible bacteria.

Q: Does Urfocin TM reduce the chance of infection coming back?

Official research summaries indicate that the medicine's long-term effects are not fully established. Specifically, there is limited evidence regarding its ability to prevent future episodes of infection.

Q: What official guidelines regarding the use of Urfocin TM in patients with heart conditions?

Official interaction data indicates this medicine may potentially increase the QTc interval, which is a measurement of electrical activity in the heart. The label notes that individuals with pre-existing heart conditions require a healthcare professional's review.

Q: Is there a generic version of Urfocin TM available?

Yes, the FDA has approved generic versions of Fosfomycin tromethamine granules for oral solution.

Q: How does Urfocin TM prevent or stop the infection?

The medicine achieves its effect through a unique mechanism of action. It works by irreversibly blocking a key step in the process bacteria use to build their cell walls, which leads to the direct death of the targeted bacteria.

Q: Are there any major black box warnings associated with Urfocin TM?

Black Box Warnings are issued by the FDA for certain prescription drugs to call attention to serious or life-threatening risks. Official regulatory labeling for this medicine does not currently contain a Black Box Warning.

How should Urfocin TM be stored and disposed of?

Urfocin (Fosfomycin trometamol granules) must be stored under specific conditions to ensure product integrity, as outlined in regulatory documentation.

Storage Requirements

Condition	Requirement
Temperature	Store at room temperature and away from excess heat.
Protection	Keep away from moisture; storage in bathrooms is prohibited.
Container	Keep in the original container with the lid tightly closed at all times.
Child Safety	Must be stored out of the sight and reach of children, utilizing safety caps.

Disposal Instructions

Expired or unused Urfocin should be disposed of according to official guidelines. The preferred method is using a drug take-back program. If this option is unavailable, the product should be mixed with an unpalatable substance (like dirt or coffee grounds) and sealed in a plastic bag before being placed in the household trash. The medicine must not be flushed down the toilet or poured down a sink.

Urfocin TM